Increasing BIN1 or decreasing DNM2 worsens pathology in a mouse model of dysferlinopathy
Disease Models & Mechanisms · 2026
DOI: 10.1242/dmm.052918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2026. Verfasst von Alice Moncheaux und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France. Hauptthemen laut MEDLINE: Dynamin II, Adaptor Proteins, Signal Transducing, Muscular Dystrophies, Limb-Girdle, Tumor Suppressor Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AFM-Téléthon, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
Dysferlinopathies are rare muscular dystrophies caused by loss-of-function variants in DYSF, which encodes dysferlin, leading to progressive muscle weakness. Although dysferlin is known for its role in membrane repair, emerging evidence suggests additional functions in membrane remodeling and T-tubule organization. Therapeutic strategies targeting the BIN1–DNM2 axis have successfully rescued T-tubule and force defects in centronuclear myopathies, raising the possibility of broader applicability. Here, we evaluated whether BIN1 overexpression or DNM2 downregulation could improve disease features in dysferlin-deficient mice through genetic crosses. Unexpectedly, both modulations worsened the Dysf−/− phenotype. BIN1 overexpression increased necrosis, fibrosis and circulating MYOM3 levels. DNM2 downregulation produced an even more severe phenotype, including additional reduced force and fiber calcification. Importantly, DNM2 protein levels were intrinsically elevated in Dysf−/− mice and biopsies from patients with dysferlinopathy. Because both strategies reduced DNM2 levels and worsened the phenotype, the elevated DNM2 levels likely represent a compensatory rather than pathogenic mechanism. Our findings demonstrate that therapeutic modulation of the BIN1–DNM2 axis has disease-specific consequences. In dysferlinopathy, DNM2 upregulation may represent a compensatory mechanism required for membrane stability, underscoring the need for context-dependent therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France.
- Institut Clinique de la Souris, PHENOMIN-ICS, 67404 Illkirch, France.
- Neuromuscular Morphology Unit, Myology Institute, Groupe Hospitalier Universitaire Pitié-Salpêtrière, 75013 Paris, France.
- Unité fonctionnelle de pathologie neuromusculaire, Department of Neuropathology, Sorbonne University, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris, 75013 Paris, France.
ORCID-Profile: Jocelyn Laporte
Förderung
- AFM-Téléthon
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
Zitieren
APA
Moncheaux, A., Lafabrie, E., Goetz-Reiner, P., Beuvin, M., Evangelista, T., & Laporte, J. (2026). Increasing BIN1 or decreasing DNM2 worsens pathology in a mouse model of dysferlinopathy. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052918
Vancouver
Moncheaux A, Lafabrie E, Goetz-Reiner P, Beuvin M, Evangelista T, Laporte J. Increasing BIN1 or decreasing DNM2 worsens pathology in a mouse model of dysferlinopathy. Disease Models & Mechanisms. 2026. doi:10.1242/dmm.052918
BibTeX
@article{Moncheaux2026,
author = {Moncheaux, Alice and Lafabrie, Emma and Goetz-Reiner, Patrice and Beuvin, Maud and Evangelista, Teresinha and Laporte, Jocelyn},
title = {Increasing BIN1 or decreasing DNM2 worsens pathology in a mouse model of dysferlinopathy},
journal = {Disease Models & Mechanisms},
year = {2026},
doi = {10.1242/dmm.052918}
}
EUVIMED